Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

Published:2020-02-24 Issue:9 Volume:34 Page:2473-2478
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Locatelli Franco,Whitlock James A.,Peters Christina^ORCID,Chen-Santel Christiane,Chia Victoria,Dennis Robyn M.,Heym Kenneth M.,Katz Aaron J.,Kelsh Michael A.,Sposto Richard,Tu Huakang,Tuglus Catherine A.,Verma Anupam,Vinti Luciana,Wilkes Jennifer J.,Zubarovskaja Nathalya,Zugmaier Gerhard,von Stackelberg Arend,Sun Weili

Funder

Amgen (Europe) GmbH

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0770-8.pdf

Reference13 articles.

1. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N. Engl J Med. 2012;366:1371–81.

2. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How i treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16.

3. Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the all-sct-bfm-2003 trial. J Clin Oncol. 2015;33:1265–74.